Implementation of a Protocol for Posaconazole Prophylaxis in Patients Undergoing Remission-Induction Chemotherapy for Acute Leukemia: From Guidelines to Real-Life
| Autor: | Ariane Morin-Quintal, Valery Lavergne |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Chemotherapy
medicine.medical_specialty Acute leukemia Posaconazole business.industry medicine.medical_treatment Incidence (epidemiology) Aspergillosis medicine.disease Surgery Infectious Diseases Oncology Internal medicine medicine Clinical endpoint Number needed to treat In patient business medicine.drug |
| Zdroj: | Open Forum Infectious Diseases. 2 |
| ISSN: | 2328-8957 |
| DOI: | 10.1093/ofid/ofv133.01 |
| Popis: | The primary endpoint was the incidence of invasive aspergillosis. In addition, we assessed the various difficulties linked to the application of the protocol. RESULTS We retrieved records for 65 patients with acute leukemia for a total of 105 courses of remission-induction chemotherapy. The incidence of proven or probable invasive aspergillosis reported was 9.7% (3 patients) in the preemptive group and 4.3% (1 patient) in the prophylaxis group. There was a 5.4% decrease in incidence, which was however not statistically significant. The number needed to treat (NNT) was 19. When including possible invasive aspergillosis, the incidence decreased from 16.1% (5 patients) without prophylaxis to 8.7% (2 patients) with posaconazole. When considering proven, probable and possible infection, the NNT was 14. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|